Allogene said Monday that clinical trials involving its off-the-shelf CAR-T therapies for blood cancer are resuming following a safety clearance by U.S. regulators.
In October, the Food and Drug Administration placed five Allogene studies on hold after a single treated patient was found to have a “chromosomal abnormality.” But a three-month investigation conducted by Allogene concluded its CAR-T called ALLO-501A was not responsible for the chromosomal abnormality, and that it had no clinical significance for the patient.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
